Kevin M. Brennan - Apr 1, 2023 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
SVP, FINANCE AND ACCOUNTING
Signature
/s/ Julia Walcott, Attorney-in-Fact
Stock symbol
XLO
Transactions as of
Apr 1, 2023
Transactions value $
$0
Form type
4
Date filed
4/3/2023, 04:11 PM
Previous filing
Apr 3, 2023
Next filing
Aug 18, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +55K $0.00 55K Apr 1, 2023 Common Stock 55K $3.17 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on April 1, 2023 and shall vest on March 30, 2024 with respect to 25% of the shares of common stock underlying the stock option, and the remaining 75% of the shares of common stock underlying the stock option shall continue to vest in 36 equal monthly installments thereafter until March 30, 2027.